ea0037gp.20.08 | Pituitary – Hypopituitarism | ECE2015
Powlson Andrew S
, Koulouri Olympia
, Steuwe Andrea
, Gillett Daniel
, Heard Sarah
, Hoole Andrew
, Scott Miriam
, Challis Benjamin G
, Antoun Nagui
, Cheow Heok K
, Mannion Richard J
, Gurnell Mark
Background: Endocrine Society guidelines classify macroprolactinomas as resistant if there is failure to normalise prolactin, or to achieve radiological tumour shrinkage of >50%, on standard doses of dopamine agonist. In this context, escalation of treatment to maximal tolerable doses and/or referral for surgery is advised. However, we have recently observed several discordant responders, where tumour shrinkage lags significantly (>6 months) beh...